- Home
- DLHC vs EPIX Comparison
DLHC vs EPIX Comparison
Compare DLHC & EPIX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DLHC
- EPIX
- Stock Information
- Founded
- DLHC 1969
- EPIX 2009
- Country
- DLHC United States
- EPIX Canada
- Employees
- DLHC N/A
- EPIX N/A
- Industry
- DLHC Business Services
- EPIX Biotechnology: Pharmaceutical Preparations
- Sector
- DLHC Consumer Discretionary
- EPIX Health Care
- Exchange
- DLHC Nasdaq
- EPIX Nasdaq
- Market Cap
- DLHC 75.1M
- EPIX 65.3M
- IPO Year
- DLHC N/A
- EPIX N/A
- Fundamental
- Price
- DLHC $3.52
- EPIX $1.79
- Analyst Decision
- DLHC
- EPIX Hold
- Analyst Count
- DLHC 0
- EPIX 3
- Target Price
- DLHC N/A
- EPIX $2.00
- AVG Volume (30 Days)
- DLHC 98.4K
- EPIX 186.2K
- Earning Date
- DLHC 04-30-2025
- EPIX 05-13-2025
- Dividend Yield
- DLHC N/A
- EPIX N/A
- EPS Growth
- DLHC 205.25
- EPIX N/A
- EPS
- DLHC 0.44
- EPIX N/A
- Revenue
- DLHC $388,869,000.00
- EPIX N/A
- Revenue This Year
- DLHC N/A
- EPIX N/A
- Revenue Next Year
- DLHC N/A
- EPIX N/A
- P/E Ratio
- DLHC $8.12
- EPIX N/A
- Revenue Growth
- DLHC N/A
- EPIX N/A
- 52 Week Low
- DLHC $2.72
- EPIX $1.40
- 52 Week High
- DLHC $12.23
- EPIX $7.88
- Technical
- Relative Strength Index (RSI)
- DLHC 41.40
- EPIX 69.44
- Support Level
- DLHC $2.72
- EPIX $1.42
- Resistance Level
- DLHC $3.89
- EPIX $1.88
- Average True Range (ATR)
- DLHC 0.35
- EPIX 0.10
- MACD
- DLHC 0.04
- EPIX 0.03
- Stochastic Oscillator
- DLHC 46.78
- EPIX 81.32
About DLHC DLH Holdings Corp.
DLH Holdings Corp is a provider of technology-enabled business process outsourcing and program management solutions in the United States. The company offers services to several government agencies which include the Department of Veteran Affairs. It is engaged in public health, performance evaluation, and health operations to solve the complex problems faced by civilian and military customers alike, leveraging digital transformation, artificial intelligence, analytics, cloud-based applications, and telehealth systems.
About EPIX ESSA Pharma Inc.
ESSA Pharma Inc is a pharmaceutical company. The company was focused on the development of small-molecule drugs for the treatment of castration-resistant prostate cancer. It was developing drugs that selectively block the amino-terminal domain of the androgen receptor, potentially overcoming the known AR-dependent resistance mechanisms of CRPC and providing CRPC patients with the potential for increased progression-free and overall survival. Currently, the company has terminated its clinical trials and other studies.